These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10781860)

  • 1. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.
    Tebbey PW; Scheuer CA; Peek JA; Zhu D; LaPierre NA; Green BA; Phillips ED; Ibraghimov AR; Eldridge JH; Hancock GE
    Vaccine; 2000 Jun; 18(24):2723-34. PubMed ID: 10781860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.
    Periwal SB; Kourie KR; Ramachandaran N; Blakeney SJ; DeBruin S; Zhu D; Zamb TJ; Smith L; Udem S; Eldridge JH; Shroff KE; Reilly PA
    Vaccine; 2003 Jan; 21(5-6):376-85. PubMed ID: 12531635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
    Siadat-Pajouh M; Cai L
    Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice.
    Walsh EE
    Vaccine; 1993; 11(11):1135-8. PubMed ID: 8249433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.
    Hancock GE; Smith JD; Heers KM
    Viral Immunol; 2000; 13(1):57-72. PubMed ID: 10733169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
    Hancock GE; Speelman DJ; Frenchick PJ; Mineo-Kuhn MM; Baggs RB; Hahn DJ
    Vaccine; 1995 Mar; 13(4):391-400. PubMed ID: 7793137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
    Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
    Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV.
    Reuman PD; Keely SP; Schiff GM
    J Med Virol; 1991 Nov; 35(3):192-7. PubMed ID: 1804931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice.
    Singh SR; Dennis VA; Carter CL; Pillai SR; Moore EG
    Viral Immunol; 2007; 20(2):261-75. PubMed ID: 17603843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit.
    Oien NL; Brideau RJ; Walsh EE; Wathen MW
    Vaccine; 1994 Jun; 12(8):731-5. PubMed ID: 8091852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus.
    Hancock GE; Hahn DJ; Speelman DJ; Hildreth SW; Pillai S; McQueen K
    Vaccine; 1994; 12(3):267-74. PubMed ID: 8165859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice.
    Goetsch L; Plotnicky-Gilquin H; Aubry JP; De-Lys P; Haeuw JF; Bonnefoy JY; Nguyen NT; Corvaïa N; Velin D
    Vaccine; 2001 Jul; 19(28-29):4036-42. PubMed ID: 11427280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.
    Hancock GE; Speelman DJ; Heers K; Bortell E; Smith J; Cosco C
    J Virol; 1996 Nov; 70(11):7783-91. PubMed ID: 8892899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel and effective intranasal immunization strategy for respiratory syncytial virus.
    Tebbey PW; Unczur CA; LaPierre NA; Hancock GE
    Viral Immunol; 1999; 12(1):41-5. PubMed ID: 10333241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
    Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
    Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.